Glioblastoma overall survival
In glioblastoma, progression-free survival (PFS) and overall survival (OS) are strongly correlated, indicating that PFS may be an appropriate surrogate for OS. Compared with OS, PFS offers earlier assessment and higher statistical power at the time of analysis 1).
Increasing the extent of resection (EOR) of GBM is associated with prolonged survival 2)
Also, adjuvant radiochemotherapy showed higher survival rates in patients with complete resection (EOR ≥ 90%), compared with partial resection (EOR < 90%) 3).
Glioblastoma IDH Mutant is associated with better outcome and increased overall survival 4).
Overall estimates of survival among patients with glioblastoma have at least doubled since 2005 to 18% at 2 years and 11% at 3 years. This may reflect treatment response to modern therapeutic approaches. However, longer-term survival remains poor and there appears to be a lack of improvement in 5-year survival 5).
Magnetic resonance perfusion imaging parameter obtained on 3-Tesla and the Ki-67 labeling index predict the overall survival of glioblastoma 6).
MR image derived texture features, tumor shape and volumetric features, and patient age were obtained for 163 patients. OS group prediction was performed for both 2-class (short and long) and 3-class (short, medium and long) survival groups. Support vector machine classification based recursive feature elimination method was used to perform feature selection. The performance of the classification model was assessed using 5-fold cross-validation. The 2-class and 3-class OS group prediction accuracy obtained were 98.7% and 88.95% respectively. The shape features used in this work have been evaluated for OS prediction of GBM patients for the first time. The feature selection and prediction scheme implemented in this study yielded high accuracy for both 2-class and 3-class OS group predictions. This study was performed using routinely acquired MR images for GBM patients, thus making the translation of this work into a clinical setup convenient 7).